The Paul Stamets Microdosing Protocol Explained

The Paul Stamets microdosing protocol is a three-part regimen combining a sub-perceptual dose of psilocybin mushrooms, lion’s mane mushroom, and niacin (vitamin B3), taken on a specific schedule. Proposed by the well-known mycologist Paul Stamets, the idea is that these three ingredients work together to promote neurogenesis and cognitive health in ways that none of them could achieve alone. The protocol has become one of the most widely discussed microdosing frameworks in the psychedelic wellness space, but the scientific evidence behind the specific combination is thinner than its popularity might suggest.

What the Protocol Actually Involves

The Stamets protocol calls for stacking three substances together as a single daily dose on a repeating schedule. The psilocybin component is a microdose, meaning an amount small enough that you should not feel any perceptual effects like visual changes or altered thinking. In practice, people typically use somewhere around 0.1 to 0.3 grams of dried psilocybin mushrooms, though the exact amount varies by individual tolerance and mushroom potency. The lion’s mane component is usually between 50 and 200 milligrams of extract, depending on the preparation. The niacin dose ranges from roughly 100 to 200 milligrams, enough to produce a noticeable skin flush in most people.

The dosing schedule is four consecutive days on, followed by three days off. This cycle repeats for about four weeks, after which you take a two- to four-week break before starting again. The days off are considered important for avoiding tolerance buildup to psilocybin, and the multi-week break is meant to prevent any long-term receptor downregulation. This on-off pattern distinguishes the Stamets protocol from other popular microdosing schedules, like James Fadiman’s one-day-on, two-days-off approach.

The Reasoning Behind Each Ingredient

Stamets has described the three components as synergistic, each playing a distinct role. Psilocybin is the centerpiece. At sub-perceptual doses, the theory is that it gently stimulates pathways associated with neuroplasticity without producing a psychedelic experience. Lion’s mane mushroom is included as a source of compounds that promote nerve growth factor, which Stamets believes complements and extends the neuroplastic effects of psilocybin. Niacin is the most unconventional piece. Stamets has theorized that the peripheral vasodilation caused by niacin’s characteristic flush helps distribute the neurochemical benefits of the other two ingredients more broadly through the body, particularly to nerve endings in the extremities. That vasodilation theory has not been tested directly, and it is worth understanding what each ingredient does on its own before evaluating how they might work together.

What Psilocybin Does in the Brain

Psilocybin, once metabolized into its active form psilocin, primarily acts on serotonin 5-HT2A receptors. At full psychedelic doses, this produces the well-known effects of altered perception, emotional intensity, and changes in self-referential thinking. At microdoses, none of that is supposed to happen. The interest in microdosing comes from the idea that even very low-level 5-HT2A activation might trigger downstream effects on brain plasticity.

The prevailing hypothesis is that psychedelics like psilocybin cause a burst of glutamate activity that leads to the release of brain-derived neurotrophic factor (BDNF), a protein critical for the growth and maintenance of neurons. BDNF then activates signaling pathways involved in building new neural connections. Researchers have found that psychedelics increase BDNF gene expression in the cortex, and that this effect is blocked when the 5-HT2A receptor is chemically shut down, which ties the neuroplastic potential directly to the same receptor system the drug targets.¹ That said, researchers have been careful to note that a definitive causal link between BDNF and psychedelic-induced neuroplasticity has not yet been fully established.

Neuroimaging studies show that psilocybin alters communication within and between major brain networks. The default mode network, a set of brain regions active during self-referential thought and mind-wandering, tends to show reduced internal connectivity after psilocybin administration.² At the same time, connectivity increases between the default mode network and other networks like the frontoparietal and salience networks, which are involved in attention and emotional processing.³ The practical interpretation is that psilocybin loosens the brain’s habitual patterns of self-focused thinking and allows more cross-talk between regions that don’t usually communicate as freely. Whether a microdose produces a milder version of this effect or something qualitatively different remains unclear, because most neuroimaging research has used moderate to full doses.

Lion’s Mane and Nerve Growth Factor

Lion’s mane (Hericium erinaceus) is an edible mushroom with a long history in traditional East Asian medicine. Its relevance to the Stamets protocol comes from two classes of compounds it contains: hericenones (found in the fruiting body) and erinacines (found primarily in the mycelium). Both have been shown to stimulate the synthesis of nerve growth factor (NGF) in nerve cells.⁴ NGF is a protein that supports the survival, growth, and differentiation of neurons, particularly in the peripheral nervous system and certain brain regions involved in memory.

Beyond NGF stimulation, lion’s mane shows broader neuroprotective properties in laboratory and animal research. It appears capable of regulating inflammatory processes, reducing oxidative stress, and protecting nerve cells from programmed cell death.⁵ In a small human trial involving young adults, a single dose of lion’s mane extract led to faster performance on a cognitive task measuring attention and response inhibition, while 28 days of supplementation showed a trend toward reduced subjective stress, though the stress result fell just short of statistical significance.⁶

The theoretical appeal of pairing lion’s mane with psilocybin is straightforward: if psilocybin promotes neuroplasticity through BDNF-related pathways and lion’s mane promotes nerve growth through NGF, combining them might produce complementary or amplified effects on neural health. It is plausible on paper. But no published study has tested the combination directly. The synergy idea is extrapolated from the individual mechanisms, not demonstrated in any controlled experiment.

Why Niacin Is in the Stack

Niacin is vitamin B3, and at the doses used in the Stamets protocol, its most noticeable effect is the “niacin flush,” a temporary reddening and warming of the skin, sometimes accompanied by tingling or itching. This flush occurs because niacin activates a specific receptor (GPR109A) in skin cells, triggering a cascade of prostaglandin release that causes blood vessels in the skin to dilate.⁷ The result is a noticeable increase in blood flow to peripheral tissues, particularly the skin.⁸

Stamets’ reasoning is that this vasodilation might help carry the active compounds from psilocybin and lion’s mane further into the peripheral nervous system, reaching nerve endings that wouldn’t otherwise get as much exposure. It is an interesting idea, but it rests on assumptions that haven’t been tested. The niacin flush is a surface-level vascular event driven by prostaglandins in skin cells, and whether it meaningfully changes the distribution of psychoactive or neurotrophic compounds through the body is unknown. Pharmacologists would point out that psilocybin’s active metabolite reaches the brain through the bloodstream regardless of peripheral vasodilation, and that NGF from lion’s mane acts locally on nerve cells rather than circulating systemically in a way that blood flow changes would obviously affect.

Some advocates suggest niacin also serves a deterrent function against recreational misuse, since the flush is uncomfortable at higher doses and would discourage someone from taking large amounts of the stack to get high. Whether Stamets intended this as a design feature or whether it is a secondary justification added by the community is debatable.

What the Evidence Shows About Microdosing Outcomes

The most important thing to know about the Stamets protocol specifically is that no published randomized controlled trial has tested this exact three-ingredient combination. The evidence that exists comes from studies of psilocybin microdosing in general, studies of lion’s mane on its own, and the pharmacology of niacin, stitched together by theoretical reasoning.

For psilocybin microdosing alone, the evidence is mixed and increasingly sobering. A large observational study of over a thousand participants found that microdosers reported greater improvements in positive mood and greater reductions in negative mood compared to non-microdosers over a one-month period. Microdosers also showed a small improvement on a psychomotor speed task. However, there were no significant differences on tests of spatial memory or sustained attention.⁹ That study was observational, meaning participants chose whether to microdose, and neither they nor the researchers were blinded to who was taking what.

When researchers have introduced proper blinding, the picture shifts. A citizen-science study where participants self-administered either microdoses or identical-looking placebos for four weeks found that both groups improved on psychological measures, with no meaningful difference between the microdose and placebo groups. Small differences that did emerge on acute measures could be explained by participants guessing correctly which group they were in.¹⁰ Two additional double-blind placebo-controlled trials found that psilocybin microdosing did not significantly affect cognitive or subjective measures compared to placebo after correcting for multiple statistical comparisons, and participants remained effectively blinded throughout, meaning they could not reliably tell whether they had received the real thing.¹¹

A systematic review examining psilocybin’s effects on cognitive function across the dose range found that processing speed and global cognition remained mostly unchanged in healthy individuals. Improvements in areas like sustained attention, working memory, and executive function showed up primarily in patients with treatment-resistant depression, a specific clinical population where the baseline is already impaired.¹² This raises the possibility that some of the benefits people attribute to microdosing may be real for those dealing with mood or cognitive difficulties, but less detectable in people who are already functioning well.

The Placebo Problem

Expectation effects loom large over the entire microdosing field. People who seek out microdosing are typically motivated, have read positive anecdotes, and already believe it works. In unblinded observational studies, this belief can easily inflate self-reported improvements in mood, creativity, and focus. The controlled studies consistently find that when participants don’t know whether they’re taking a microdose or a placebo, the differences shrink to nearly nothing.

This does not necessarily mean microdosing is useless. Placebo effects are real physiological responses, and if someone genuinely feels better, that matters on a personal level. But it does mean the specific pharmacological claims behind the Stamets protocol, that psilocybin, lion’s mane, and niacin are doing something special at the molecular level that a sugar pill could not, remain unproven. The stack’s popularity is driven more by Stamets’ reputation and the compelling logic of the combination than by clinical data showing it works as described.

Safety Considerations

Because the protocol involves chronic use over weeks or months, safety questions are worth taking seriously even at sub-perceptual doses. One emerging concern involves psilocybin’s activity at the serotonin 5-HT2B receptor. Chronic activation of this receptor has been linked to valvular heart disease in other drug contexts, and laboratory research has found that psilocybin and several other psychedelics can bind to 5-HT2B with potency comparable to their binding at the 5-HT2A receptor. Safety margins relative to the blood levels expected from typical microdoses appear wider than those of known heart-valve-damaging drugs, but researchers have concluded that valvular heart disease remains a potential risk with chronic microdosing and needs further study.¹³ This risk is theoretical at current microdose levels but worth monitoring, especially for anyone microdosing on a prolonged timeline.

Niacin at the doses used in the protocol carries its own side effects. Beyond the flush, which is uncomfortable but harmless for most people, niacin has been associated with gastrointestinal upset, skin rash, fatigue, and at higher doses, liver dysfunction. Side effects tend to be dose-dependent and usually resolve when the dose is reduced or stopped.¹⁴ People with kidney problems or liver conditions should be particularly cautious, as their ability to clear niacin is compromised. For healthy adults at the doses typically discussed in the Stamets protocol, serious niacin side effects are uncommon, but the flush itself can be intense enough that some people abandon the protocol after a few days.

Lion’s mane has a generally favorable safety profile in the limited human research available. Allergic reactions are possible, particularly in people with mushroom sensitivities, and gastrointestinal discomfort has been reported occasionally. But compared to the other two components, lion’s mane raises fewer safety flags at typical supplemental doses.

The Lion’s Mane Quality Problem

One underappreciated issue with the Stamets protocol is that not all lion’s mane supplements are equivalent. The two compound classes of interest, hericenones and erinacines, are found in different parts of the mushroom. Hericenones are present in the fruiting body (the part that looks like a white, shaggy pom-pom), while erinacines are produced primarily in the mycelium, the root-like network that grows through the substrate. Research has shown that erinacine production is substantially greater in mycelial tissue than in fruit body tissue.¹⁵

This matters because the lion’s mane supplement market is split between products made from fruiting bodies and those made from mycelium grown on grain. Fruiting body supplements will be richer in hericenones but contain few or no erinacines, while mycelium-on-grain products may contain erinacines but are often diluted by the starchy grain substrate. Neither type necessarily delivers the full spectrum of bioactive compounds used in the research that underpins the protocol’s rationale. Some products marketed as lion’s mane have been found to contain mostly grain filler with minimal mushroom-derived compounds. If you’re following the protocol, the form and quality of the lion’s mane supplement you choose makes a genuine difference, and the label alone may not tell you enough.

Psilocybin Dose Variability and Legal Status

A separate practical challenge is psilocybin dosing accuracy. Unlike pharmaceutical drugs manufactured to exact specifications, dried psilocybin mushrooms vary in potency depending on species, growing conditions, and even which part of the mushroom you consume. Two seemingly identical 0.1-gram portions of the same species can contain meaningfully different amounts of psilocybin. This means that what functions as a genuine sub-perceptual microdose one day could cross into mildly perceptible territory the next, which creates both discomfort and inconsistency in any protocol that depends on precise dosing over weeks.

There is also the legal reality. Psilocybin remains a controlled substance in most jurisdictions, classified as Schedule I in the United States and similarly restricted across much of Europe and Asia. A handful of cities and states have decriminalized personal possession or use, and Oregon has created a supervised therapeutic-use framework, but in most places, obtaining, possessing, or using psilocybin mushrooms carries legal risk regardless of the dose. The Stamets protocol circulates widely online as though it were a wellness routine you can simply start, which obscures the fact that doing so is illegal for the vast majority of people who encounter it.

How the Stamets Protocol Compares to Other Schedules

Several microdosing schedules circulate in the community, and the choice between them comes down to philosophy more than evidence. The Fadiman protocol uses one microdose day followed by two off days, repeating for several weeks. It was designed to allow users to compare microdose days, off days, and transition days, making it easier to notice effects. The Stamets protocol’s four-days-on, three-days-off pattern front-loads the active days and may produce a more sustained exposure during the “on” phase, though whether this translates to different outcomes is unknown.

What genuinely sets the Stamets protocol apart from other schedules is not the timing but the stacking. Most other microdosing approaches involve psilocybin alone. The addition of lion’s mane and niacin is Stamets’ distinctive contribution, and it reflects his career-long conviction that functional mushrooms have underexplored therapeutic potential. Whether that conviction translates into a measurably superior protocol remains an open question. The individual ingredients each have biological plausibility behind them, but the specific claim that they work synergistically at these doses, on this schedule, in this combination, has not been tested in any published trial. For now, the Stamets stack is best understood as a carefully reasoned hypothesis from a knowledgeable mycologist, not a clinically validated treatment.